Mineralys Therapeutics, Inc. (MLYS)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesUS6031701013
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Mineralys Therapeutics, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 15:14. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 11 Feb 2027 16:00 | -0.67 | — | — | Upcoming |
| 04 Nov 2026 16:00 | -0.55 | -0.64 | -15.9% | Miss |
| 11 Aug 2026 16:00 | -0.53 | -2.85 | -432.7% | Miss |
| 06 May 2026 16:00 | -0.44 | -0.47 | -6.8% | Miss |
| 12 Mar 2026 16:00 | -0.52 | -0.40 | +22.5% | Beat |
| 10 Nov 2025 16:00 | -0.61 | -0.52 | +15.2% | Beat |
| 12 Aug 2025 16:00 | -0.74 | -0.66 | +10.6% | Beat |
| 12 May 2025 16:00 | -0.98 | -0.79 | +19.6% | Beat |
| 12 Feb 2025 07:00 | -1.08 | -0.98 | +9.0% | Beat |
| 11 Nov 2024 16:00 | -0.83 | -1.13 | -35.4% | Miss |
| 13 Aug 2024 16:00 | -0.70 | -0.83 | -18.6% | Miss |
| 09 May 2024 07:00 | -0.67 | -0.70 | -4.8% | Miss |
| 21 Mar 2024 07:00 | -0.82 | -0.61 | +26.1% | Beat |
| 07 Nov 2023 16:00 | -0.76 | -0.57 | +25.0% | Beat |
| 07 Aug 2023 16:00 | -0.72 | -0.31 | +56.9% | Beat |
| 15 May 2023 16:00 | -0.89 | -0.51 | +42.7% | Beat |
| 15 Mar 2023 16:00 | -1.72 | -1.74 | -1.2% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 0 | — | -154.7M | — | -2.29 | +37.4% | -142.4M |
| 2024 | 0 | — | -177.8M | — | -3.66 | -83.9% | -166.4M |
| 2023 | 0 | — | -71.9M | — | -1.99 | -160.8% | -81.2M |
| 2022 | 0 | — | -29.8M | — | -0.76 | — | -29.2M |
| 2021 | — | — | — | — | — | — | — |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 18.27 | 18.29 | 14.86 | 15.03 | -17.33% | 22,633,922 | |
| Oct 2026 | 25.13 | 25.34 | 18.11 | 18.18 | -27.66% | 33,227,000 | |
| Sep 2026 | 25.47 | 31.99 | 24.43 | 25.13 | -2.10% | 31,783,400 | |
| Aug 2026 | 25.80 | 28.09 | 24.95 | 25.67 | +0.59% | 16,664,000 | |
| Jul 2026 | 26.72 | 31.11 | 25.20 | 25.52 | -5.41% | 17,410,100 | |
| Jun 2026 | 30.99 | 31.92 | 22.30 | 26.98 | -14.35% | 49,273,900 | |
| May 2026 | 27.75 | 32.14 | 25.64 | 31.50 | +18.20% | 24,938,000 | |
| Apr 2026 | 28.01 | 31.48 | 25.16 | 26.65 | -1.62% | 23,347,900 | |
| Mar 2026 | 29.08 | 31.00 | 22.42 | 27.09 | -7.42% | 31,504,500 | |
| Feb 2026 | 30.89 | 32.21 | 26.85 | 29.26 | -5.28% | 21,512,500 | |
| 36 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Mineralys stock gains after drug shows sustained blood pressure cuts (opens in a new tab) Investing.com · 09 Nov 2026 17:59
- Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026 (opens in a new tab) 08 Nov 2026 21:35
- Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (opens in a new tab) 06 Nov 2026 13:00
- Mineralys: Fairly Valued Near $17 As Baxfendy Launch Validates Slow ASI Ramp (Upgrade) (opens in a new tab) SeekingAlpha · 05 Nov 2026 12:29
- Mineralys Therapeutics Inc (MLYS) Q3 2026 Earnings Call Highlights: Strong Phase 3 Data and ... (opens in a new tab) GuruFocus.com · 05 Nov 2026 07:13
- Mineralys Therapeutics (MLYS) Publishes Lorundrostat CKD Data, Is The Stock Still A Bargain? (opens in a new tab) Simply Wall St. · 05 Nov 2026 05:18
- What Mineralys Therapeutics (MLYS) Said on Its Q3 Earnings Call (opens in a new tab) MarketBeat · 05 Nov 2026 03:14
- Kidney Trial Results Could Change The Case For Mineralys Therapeutics Stock (opens in a new tab) Simply Wall St. · 01 Nov 2026 10:12
- Mineralys Therapeutics (MLYS) Shares New Lorundrostat Data, Is The Stock A Bargain? (opens in a new tab) Simply Wall St. · 13 Oct 2026 00:26
- Mineralys Therapeutics (MLYS) Faces A Fresh Valuation Test On New Lorundrostat Data (opens in a new tab) Simply Wall St. · 28 Sep 2026 18:08
- Mineralys (MLYS) Q2 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 19 Aug 2026 00:13
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 15.50 USD
- Market cap
- 1.4B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow MLYS and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.